The Shared Savings Program serves as down payment on the future promise of biosimilars. At a time when many people are having to make difficult decisions related to how to afford their medications, this program will offer some direct financial relief and position customers and their employers to recognize greater long-term cost savings.
Business Practice
CME/CE
Subscribe
BIOSIMILAR APPROVALS
- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Cigna Offers Patients $500 Debit Card to Switch to Biosimilars
Cigna said it will push biosimilar forms of infliximab onto the preferred list and reward patients who make the switch.
With specialty drug costs commanding an ever-larger share of the total pharmacy spend, the pharmacy benefit manager Cigna is unrolling a shared savings program that, among its signature features, offers patients a $500 health services/products gift card for switching to a biosimilar.
The plan is expected to be rolled out in July 2021 with more information presented to patients, but in announcing the program, Cigna Chief Clinical Officer Steve Miller stated that a chief goal is to reduce current spending on the infliximab originator product Remicade, which he said costs $30,000 yearly for an average regimen of infusions, “but may be much higher depending on site of administration.”
“While life-saving and life-changing, this [medicine] presents a significant challenge for health plans and can be financially devastating for patients,” he said.
Also, Cigna will move 2 infliximab biosimilars, Avsola and Inflectra, up to preferred status on formulary to get patients and health care providers to use them.
Infliximab is used in the treatment of rheumatoid arthritis and other types of autoimmune diseases. Infliximab biosimilars have seen slow uptake compared with other biosimilars. Clinical investigators have speculated that physicians are more reluctant to switch patients to a biosimilar form of infliximab once hard-to-manage chronic autoimmune conditions are brought under control with the reference product.
Infliximab Market Share Data
After 3 years on the market, infliximab biosimilars had achieved just 20% of the total market for infliximab, according to a 2020 report from Amgen. However, steep declines were noted in average sales price (ASP) for the reference product and the biosimilars available at that time, indicating that biosimilar competitive pressure had succeeded in lowering overall costs of infliximab.
By the second quarter of 2020, Remicade’s ASP had dropped 33%, and the 2 biosimilars on the market at that time, Inflectra and Renflexis, had seen ASP price drops of 43% and 40%, respectively. In July 2020, Amgen launched the infliximab biosimilar Avsola. The respective ASPs at the time for Remicade, Inflectra, Renflexis, and Avsola were $483, $471, $486, and $500.
Manufacturer deals and rebates can cloud the picture of how much is actually paid for biosimilars vs originator products, and Cigna did not provide actual figures on how much it expects to save.
The competitive pricing pressure from biosimilars has the potential to reduce drug spending by at least $225 billion by 2031, Miller said, citing an Evernorth analysis of drug price data that factored in not just the 20 biosimilars already on the market but also biosimilars that may arrive based on pending patent expirations for some key biologic originator products.
To qualify for the $500 debit card, patients enrolled in Cigna plans would have to switch to a biosimilar or another preferred medication.
“The shared savings program serves as a down payment on the future promise of biosimilars. At a time when many people are having to make difficult decisions related to how to afford their medications, this program will offer some direct financial relief and position customers and their employers to recognize greater long-term cost savings,” Miller said.
Recent Videos
Related Content
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024Podcast
On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Stable Patient Satisfaction Found After Switching From the Humira or Biosimilar CT-P17
December 14th 2024Article
A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024Podcast
On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Article
Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Similar Persistence Rates Between Adalimumab New Starts, Switched Patients
December 7th 2024Article
A French real-world study found that the adalimumab biosimilar SB5 was effective in treating rheumatic or gastrointestinal immune-mediated inflammatory diseases, showing no loss of disease control in switched patients and similar persistence rates between naive and switched groups.
